iCOR Medical, a medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K260383) for the iCOR Beat, a prescription-only, single-lead ECG monitor that records continuously for up to 14 days (STR model) or 30 days (LTR model). iCOR Beat is designed to make ambulatory cardiac monitoring simpler for patients and more actionable for the physicians who order it.
CORAL SPRINGS, Fla., Nov. 16, 2026 /PRNewswire-PRWeb/ -- iCOR Beat is indicated for adults 18 and older who may be asymptomatic or who may have transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, chest pain or anxiety.
ECG data can be transferred over Bluetooth through the BeatSuite Mobile app to iCOR's BeatSuite platform for review by healthcare providers. Data can also be recovered from the device if wireless transfer is incomplete.
Because iCOR Beat is affordable, providers can let patients keep it at the end of the test, eliminating return shipping and device reprocessing.
Designed for Digital Health Pathways
iCOR Medical built its cardiac diagnostic infrastructure for the digital health era. "Our partner-branded cardiac monitoring program is designed for scalable population deployment through strategic partnerships with wearables companies, telemedicine providers, membership lab platforms, and other digital health pathways," said Jon Fedele, co-founder and board member.
Through a simple integration with iCOR's BeatSuite platform, companies gain access to a national cardiac testing facility without building their own. "They manage their members and take payment through their own app, and we do the rest," said Fedele. iCOR manages the infrastructure, including inventory, shipping, patient support, report generation and interpretation by cardiologists in all 50 states.
Improved Patient Experience
iCOR Beat is designed to support earlier diagnosis without disrupting the patient's life. Key features include:
- Form factor — lightweight and low-profile for all-day wear, weighing about 1 ounce (28g)
- Wear time — continuous recording for up to 14 or 30 days, depending on model, with no battery changes or charging
- Comfort and daily life — standard snap ECG electrodes, changed every 48 hours or after showering to limit skin irritation, and an IP55 rating against dust and water spray
- Convenience — ECG data can be sent through the BeatSuite Mobile app over Bluetooth
"iCOR Beat represents a major advancement in ambulatory cardiac monitoring for patients and physicians. Small and lightweight for improved patient comfort, while its simple application, continuous recording for up to 30 days, and streamlined data transfer make extended monitoring easy to incorporate into everyday life," said Lee A. Surkin, MD, a board-certified cardiologist and chief medical officer of iCOR Medical.
Addressing an Underdiagnosed Condition
Atrial fibrillation (AFib) is the most common heart arrhythmia, and researchers project that 12.1 million people in the U.S. will have AFib by 2030¹. People with AFib face roughly five times the risk of ischemic stroke². Because episodes can be intermittent or produce no symptoms, many cases go undetected without extended monitoring. Accessible ambulatory monitoring helps physicians identify these rhythms sooner and begin treatment earlier.
About iCOR Medical
iCOR Medical is a medical technology company focused on expanding access to cardiac care by making heart rhythm monitoring affordable and easy to deploy, so more patients can be diagnosed earlier and at scale. The company's leadership previously founded companies in at-home cardiac and sleep diagnostics, home health and durable medical equipment. Learn more at icormedical.com.
Investor Relations
Candido Sosa, CFO | [email protected]
Media Contact
Kyle Miko, Co-founder and Board Member | [email protected]
References
¹Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
²Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
SOURCE iCOR Medical


Share this article